Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | CTSB | P07858 | 2/20 | 0.31 |
| ▸ | CTSH | P09668 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245703 | 0.82 | TSHR (0.40) | EPHX1PDE4BPOLBNPSR1TSHR | |
| SCHEMBL1169668 | 0.82 | TSHR (0.40) | EPHX1PDE4BPOLBNPSR1TSHR | |
| SCHEMBL1246352 | 0.82 | TSHR (0.40) | EPHX1PDE4BPOLBNPSR1TSHR | |
| SCHEMBL1245700 | 0.82 | TSHR (0.40) | EPHX1PDE4BPOLBNPSR1TSHR | |
| SCHEMBL1170184 | 0.81 | TSHR (0.39) | EPHX1PDE4BPOLBNPSR1TSHR | |
| SCHEMBL19085525 | 0.79 | SLC6A2 (0.40) | EPHX1 | |
| SCHEMBL1169927 | 0.78 | TSHR (0.40) | EPHX1PDE4BPOLBNPSR1TSHR | |
| SCHEMBL30553085 | 0.76 | ACE (0.41) | — | |
| SCHEMBL3288846 | 0.76 | EPHX1 (0.50) | EPHX1PDE4BPOLBNPSR1TSHR | |
| SCHEMBL1296538 | 0.76 | SLC6A2 (0.40) | PDE4BPOLBNPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | EPHX1 4437/4885PDE4B 4322/4885PKM 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.